Nononcologic Use of Human Recombinant Erythropoietin Therapy in Hospitalized Patients
نویسندگان
چکیده
منابع مشابه
Nononcologic use of human recombinant erythropoietin therapy in hospitalized patients.
BACKGROUND Human recombinant erythropoietin (rHuEPO) is widely used to stimulate red blood cell production in patients with anemia due to cancer, renal disease, and other medical conditions, but concern has grown about its overuse and potential for harm. Little is known about the nature of rHuEPO use in hospitalized patients who receive rHuEPO therapy for nononcologic indications. METHODS We ...
متن کاملResistance to recombinant human erythropoietin therapy in haemodialysis patients
The involvement of a humoral factor (named as haemopoietin) in the regulation of haematopoiesis, was firstly described in literature in 1906 (Carnot Deflandre, 1906). However, only 40 years later a linkage between erythropoietin (EPO) and erythropoiesis was described (Bondsdorff Jalavisto, 1948), and only in the 1950s was established that the kidney is the main site of production of EPO (Ja...
متن کاملSafe and efficacious use of recombinant human erythropoietin in malignancy.
Recombinant human erythropoietic proteins (rhEpo) can be used in anaemic patients with malignancy receiving chemotherapy to reduce transfusion requirements and improve quality of life. It is highly efficacious when used with appropriate intravenous (iv) iron supplementation to combat functional iron deficiency. There is no indication that rhEpo improves either survival or the outcome of treatme...
متن کاملUse of Cuban recombinant human erythropoietin in Parkinson's disease treatment.
INTRODUCTION Recombinant human erythropoietin is used primarily to treat anemia. There is evidence of its neuroprotective capacity from preclinical studies in Parkinson's disease and other neurodegenerative diseases. Recombinant human erythropoietin produced in Cuba (ior-EPOCIM) is registered and approved for use in humans in Cuba and in a number of other countries. OBJECTIVE Assess safety an...
متن کاملHemodynamic changes by recombinant erythropoietin therapy in hemodialyzed patients.
Recombinant human erythropoietin therapy was given to 15 patients undergoing long-term hemodialysis with normal cardiac function. None of the patients had hypertension before the erythropoietin therapy and had received no antihypertensive agents. Before and after the erythropoietin therapy M-mode and pulsed Doppler echocardiographic studies, measurements of plasma volume by radioiodinated human...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Archives of Internal Medicine
سال: 2007
ISSN: 0003-9926
DOI: 10.1001/archinte.167.8.840